The sepsis market is constrained by a limited number of approved treatments and a high unmet need. However, the launch of emerging therapies, such as VBI-S (Vivacelle Bio), Enibarcimab (AdrenoMed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback